BlackBoxRX
 
We highly recommend enabling Javascript while using the BlackBoxRX site.

Glecaprevir/Pibrentasvir

Risk of Hepatitis B Virus Reactivation in Patients Coninfectd with HCV and HBV

  • Test all patients for evidence of current or prior hepatitis B virus (HBV) infection before initiating treatment with MAVYRET. HBV reactivation has been reported in HCV/HBV coinfected patients who were undergoing or had completed treatment with HCV direct-acting antivirals and were not receiving HBV antiviral therapy. Some cases have resulted in fulminant hepatitis, hepatic failure, and death. Monitor HCV/HBV coinfected patients for hepatitis flare or HBV reactivation during HCV treatment and post-treatment follow-up. Initiate appropriate patient management for HBV infection as clinically indicated¬†[see Warnings and Precautions¬†(5.1)].

FDA and Industry Communications

Index to FDA Safety Information

Patient Counseling Information

Package Inserts

Glecaprevir/Pibrentasvir

Updated September 2017